Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454284 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Type I Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,114
- Enrollment target
NCT01454284 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,114 participants.
The verdict
NCT01454284, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,114 participants
- Enrollment target
Study Summary
The purpose of this study is: * To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. * To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment. * To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 52 weeks of treatment. * To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment
Interventions
- DRUG Glargine
- DRUG Insulin Lispro
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,114 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454284
The ClinicalTrials.gov registry entry for NCT01454284 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glargine is the first listed.
NCT01454284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454284 about?
NCT01454284 is a clinical study titled "A Study in Participants With Type I Diabetes Mellitus". The purpose of this study is: * To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. * To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment. * To compare the number of participants on LY26...
What is the current status of trial NCT01454284?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,114 participants. The study started on 2012-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01454284?
The interventions under investigation include: Glargine (DRUG), Insulin Lispro (DRUG), LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01454284?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.